4D MOLECULAR THERAPEUTICS IN's ticker is FDMT and the CUSIP is 35104E100. A total of 81 filers reported holding 4D MOLECULAR THERAPEUTICS IN in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $29,000 | -99.5% | 3,573 | -99.6% | 0.01% | -99.5% |
| Q2 2022 | $6,014,000 | -77.3% | 861,607 | -50.9% | 2.05% | -47.4% |
| Q1 2022 | $26,543,000 | -19.9% | 1,755,506 | +16.3% | 3.90% | +3.8% |
| Q4 2021 | $33,128,000 | +11.7% | 1,509,944 | +37.3% | 3.76% | -30.3% |
| Q3 2021 | $29,665,000 | +30.3% | 1,099,944 | +16.3% | 5.39% | -8.9% |
| Q2 2021 | $22,765,000 | +74.4% | 945,382 | +214.2% | 5.92% | +150.7% |
| Q1 2021 | $13,052,000 | +1474.4% | 300,886 | +1404.4% | 2.36% | +1271.5% |
| Q4 2020 | $829,000 | – | 20,000 | – | 0.17% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| VR Adviser, LLC | 3,000,000 | $38,190,000 | 4.02% |
| Casdin Capital, LLC | 1,033,811 | $13,160,414 | 1.46% |
| BVF INC/IL | 4,007,413 | $51,014,367 | 1.38% |
| Deep Track Capital, LP | 2,778,107 | $35,365,302 | 1.36% |
| Opaleye Management Inc. | 308,500 | $3,927,205 | 1.28% |
| Eagle Health Investments LP | 437,911 | $5,574,607 | 1.23% |
| Novo Holdings A/S | 1,200,000 | $15,276,000 | 1.13% |
| RA Capital Management | 4,163,211 | $52,997,676 | 1.04% |
| VIKING GLOBAL INVESTORS LP | 4,787,914 | $60,950,145 | 0.25% |
| HighVista Strategies LLC | 33,419 | $425,424 | 0.20% |